LifeVantage Corporation (OTCBB: LFVN), the maker of Protandim, announced a second patent was awarded in June, 2008 for its Protandim antioxidant therapy product. Protandim is clinically proven to slow the progressive rate of aging by reducing oxidative stress, which is a key factor in aging. Researchers believe that Protandim’s unique ability to reduce aging factors at the cellular level will play a pivotal role in helping consumers age gracefully. The newly issued patent is entitled, “Preparation of Compositions to Alleviate Inflammation and Oxidative Stress in a Mammal.”
Dr. Joe McCord, one of the foremost authorities on the body’s antioxidant defense system and the co-discoverer of the important antioxidant enzyme superoxide dismutase, said, “The granting of this second U.S. patent underscores the unique ability of Protandim to modulate important physiological events involved in the inflammatory process, and known to be common to hundreds of human diseases and to the aging process itself. Because of the remarkable synergy of Protandim’s five phytochemical components working together to increase the body’s network of antioxidant enzymes, it achieves protection against oxidative stress that greatly exceeds that produced by conventional therapies.”
David Brown, CEO and president of LifeVantage, said, “Our mission is to develop science-based, natural solutions for healthy aging. Health and wellness is a primary concern for our partners including our customers, retailers and healthcare professionals. The issuance of a second patent for Protandim further supports the fact that there is no other product in the marketplace that can provide consumers a proven solution in reducing the negative effects caused by oxidative stress, which is the primary culprit in aging.”
Popularity: 1% [?]
